A Linear Dose-Response Relationship between Fasting Plasma Glucose and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
A Linear Dose-Response Relationship between Fasting Plasma Glucose and Colorectal Cancer Risk: Systematic Review and Meta-analysis.
复制标题
空腹血糖与结直肠癌风险之间的线性剂量反应关系：系统评价和荟萃分析。
DOI：
10.1038/srep17591
复制
发表时间：
2015-12-01
影响因子：
4.6
通讯作者：
Cai K
中科院分区：
文献类型：
--
作者：
Shi J;Xiong L;Li J;Cao H;Jiang W;Liu B;Chen X;Liu C;Liu K;Wang G;Cai K
多年来，作为前驱糖尿病、糖尿病和代谢综合征的一种表现形式，高血糖是否是结直肠癌的危险因素，这一问题一直被广泛研究。事实上，即使在几项前瞻性研究得出结论之后，这个话题仍然存在争议。我们进行了一项系统回顾和荟萃分析，以调查血糖浓度与结直肠癌发病率之间的剂量-反应关系。空腹血糖（FPG）与结直肠癌风险呈线性（非线性P = 0.303）剂量-反应关系，无显著异质性。FPG每增加20 mg/dL，结直肠癌的相对危险度（RR）为1.015 （95% CI: 1.012-1.019, P = 0.000）。在亚组分析中，结肠癌（CC）和直肠癌（RC）研究的合并RRs分别为1.035 （95% CI 1.008-1.062, P = 0.011）和1.031 (95% CI: 0.189-5.628, P = 0.972)；在比较男性和女性的分析中，合并的rr分别为1.016 （95% CI: 1.012-1.020, P = 0.000）和1.011 （95% CI: 0.995-1.027, P = 0.164）。两种方法的敏感性分析结果相似。综上所述，FPG与结直肠癌发病风险之间存在显著的线性剂量-反应关系。对于患有糖尿病或前驱糖尿病的人来说，控制血糖可能有助于预防结直肠癌。
For many years, the question of whether hyperglycaemia, a manifestation of prediabetes, diabetes mellitus and metabolic syndrome, is a risk factor for colorectal cancer has been intensely studied. In fact, even after the conclusion of several prospective studies, the topic is still controversial. We conducted a systematic review and meta-analysis to investigate the dose-response relationship between blood glucose concentration and the incidence of colorectal cancer. A linear (P = 0.303 for non-linearity) dose-response relationship was observed between fasting plasma glucose (FPG) and colorectal cancer risk without significant heterogeneity. The relative risk (RR) for colorectal cancer per 20 mg/dL increase in FPG was 1.015 (95% CI: 1.012–1.019, P = 0.000). In subgroup analyses, the pooled RRs for colon cancer (CC) and rectal cancer (RC) studies were 1.035 (95% CI 1.008–1.062, P = 0.011) and 1.031 (95% CI: 0.189–5.628, P = 0.972), respectively; in the analysis comparing men and women, the pooled RRs were 1.016 (95% CI: 1.012–1.020, P = 0.000) and 1.011 (95% CI: 0.995–1.027, P = 0.164), respectively. Sensitivity analyses using two methods showed similar results. In conclusion, there is a significant linear dose-response relationship between FPG and the incidence risk of colorectal cancer. For people with diabetes or prediabetes, controlling blood glucose might be useful to prevent colorectal cancer.